NCT06803693View on ClinicalTrials.gov

Efficacy and Safety of Pola-RCHP-X Vs Pola-RCHP in Untreated DLBCL

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

December 31, 2028

Conditions
Diffuse Large B-Cell Lymphoma
Interventions
DRUG

Polatuzumab vedotin

Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Rituximab

Rituximab IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Cyclophosphamide

Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Doxorubicin

Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Prednisone

Prednisone PO will be administered as per the schedule specified in the respective arm.

DRUG

Zanubrutinib

Zanubrutinib PO will be administered as per the schedule specified in the respective arm.

DRUG

Lenalidomide

Lenalidomide PO will be administered as per the schedule specified in the respective arm.

DRUG

Decitabine

Decitabine IV infusion will be administered as per the schedule specified in the respective arm.

All Listed Sponsors
lead

Ruijin Hospital

OTHER